Skip to main content
Top
Published in: Inflammation 4/2022

28-03-2022 | Multiple Sclerosis | Original Article

Identification of Potential Biomarkers in the Peripheral Blood Mononuclear Cells of Relapsing–Remitting Multiple Sclerosis Patients

Authors: Marjan Golabi, Farshid Fathi, Morteza Samadi, Mohammad Sadegh Hesamian, Nahid Eskandari

Published in: Inflammation | Issue 4/2022

Login to get access

Abstract

Multiple sclerosis (MS) is described as an immune disorder with inflammation and neurodegeneration. Relapsing–remitting MS (RRMS) is one of the most common types of MS. The diagnostic manner for this disorder typically includes the usage of magnetic resonance imaging (MRI); however, this is not always a very precise diagnostic method. Identification of molecular biomarkers in RRMS body fluids samples compared to healthy subjects can be useful to indicate the normal and pathogenic biological processes or pharmacological responses to drug interaction. In this regard, this study evaluated different miRNAs in isolated peripheral blood mononuclear cells (PBMCs) of RRMS compared to controls and their correlations with altered T regulatory type 1 (Tr1) cells, osteopontin (OPN), and interleukin 10 (IL-10) levels. The frequency of Tr1 cells was measured using flow cytometry. Also, the expressions of different miRNAs were evaluated via quantitative real-time polymerase chain reaction (RT-qPCR) and plasma levels of IL-10 and OPN were tested by enzyme-linked immunosorbent assay (ELISA). The obtained results showed the Tr1 cells’ frequency, Let7c-5p, and miR-299-5p levels decreased in RRMS patients to about 59%, 0.69%, and 20% of HCs, respectively, (P < 0.05). The miR-106a-5p levels increased about 7.5-fold in RRMS patients in comparison to HCs (P < 0.05). Moreover, the results showed that there was an increased negative association between Tr1 frequency and plasma-OPN levels in RRMS patients in comparison to HCs and also, we found a moderate positive correlation between plasma-IL-10 and miR-299-5p expression of RRMS patients. Overall, it may be possible to use these biomarkers to improve the diagnostic process. These biomarkers may also be considered for clinical and therapeutic studies in the future.

Graphical abstract

Literature
1.
go back to reference Trapp, B.D., and K.-A. Nave. 2008. Multiple sclerosis: An immune or neurodegenerative disorder? Annual Review of Neuroscience 31: 247–269.CrossRef Trapp, B.D., and K.-A. Nave. 2008. Multiple sclerosis: An immune or neurodegenerative disorder? Annual Review of Neuroscience 31: 247–269.CrossRef
2.
go back to reference Lublin, F.D., S.C. Reingold, J.A. Cohen, G.R. Cutter, P.S. Sørensen, A.J. Thompson, et al. 2014. Defining the clinical course of multiple sclerosis: The 2013 revisions. Neurology 83 (3): 278–286.CrossRef Lublin, F.D., S.C. Reingold, J.A. Cohen, G.R. Cutter, P.S. Sørensen, A.J. Thompson, et al. 2014. Defining the clinical course of multiple sclerosis: The 2013 revisions. Neurology 83 (3): 278–286.CrossRef
3.
go back to reference Rocca, M.A., P. Valsasina, V. Martinelli, P. Misci, A. Falini, G. Comi, et al. 2012. Large-scale neuronal network dysfunction in relapsing-remitting multiple sclerosis. Neurology 79 (14): 1449–1457.CrossRef Rocca, M.A., P. Valsasina, V. Martinelli, P. Misci, A. Falini, G. Comi, et al. 2012. Large-scale neuronal network dysfunction in relapsing-remitting multiple sclerosis. Neurology 79 (14): 1449–1457.CrossRef
4.
go back to reference Dobson, R., and G. Giovannoni. 2019. Multiple sclerosis—a review. European journal of neurology. 26 (1): 27–40.CrossRef Dobson, R., and G. Giovannoni. 2019. Multiple sclerosis—a review. European journal of neurology. 26 (1): 27–40.CrossRef
5.
go back to reference Dilokthornsakul, P., R.J. Valuck, K.V. Nair, J.R. Corboy, R.R. Allen, and J.D. Campbell. 2016. Multiple sclerosis prevalence in the United States commercially insured population. Neurology 86 (11): 1014–1021.CrossRef Dilokthornsakul, P., R.J. Valuck, K.V. Nair, J.R. Corboy, R.R. Allen, and J.D. Campbell. 2016. Multiple sclerosis prevalence in the United States commercially insured population. Neurology 86 (11): 1014–1021.CrossRef
6.
go back to reference Hosseinzadeh, A., M. Baneshi, B. Sedighi, J. Kermanchi, and A. Haghdoost. 2019. Incidence of multiple sclerosis in Iran: A nationwide, population-based study. Public Health 175: 138–144.CrossRef Hosseinzadeh, A., M. Baneshi, B. Sedighi, J. Kermanchi, and A. Haghdoost. 2019. Incidence of multiple sclerosis in Iran: A nationwide, population-based study. Public Health 175: 138–144.CrossRef
7.
go back to reference Venken, K., N. Hellings, T. Broekmans, K. Hensen, J.-L. Rummens, and P. Stinissen. 2008. Natural naive CD4+ CD25+ CD127 low regulatory T cell (Treg) development and function are disturbed in multiple sclerosis patients: Recovery of memory Treg homeostasis during disease progression. The Journal of Immunology. 180 (9): 6411–6420.CrossRef Venken, K., N. Hellings, T. Broekmans, K. Hensen, J.-L. Rummens, and P. Stinissen. 2008. Natural naive CD4+ CD25+ CD127 low regulatory T cell (Treg) development and function are disturbed in multiple sclerosis patients: Recovery of memory Treg homeostasis during disease progression. The Journal of Immunology. 180 (9): 6411–6420.CrossRef
8.
go back to reference Campbell, G.R., J.T. Worrall, and D.J. Mahad. 2014. The central role of mitochondria in axonal degeneration in multiple sclerosis. Multiple Sclerosis Journal. 20 (14): 1806–1813.CrossRef Campbell, G.R., J.T. Worrall, and D.J. Mahad. 2014. The central role of mitochondria in axonal degeneration in multiple sclerosis. Multiple Sclerosis Journal. 20 (14): 1806–1813.CrossRef
9.
go back to reference Mahad, D.H., B.D. Trapp, and H. Lassmann. 2015. Pathological mechanisms in progressive multiple sclerosis. The Lancet Neurology. 14 (2): 183–193.CrossRef Mahad, D.H., B.D. Trapp, and H. Lassmann. 2015. Pathological mechanisms in progressive multiple sclerosis. The Lancet Neurology. 14 (2): 183–193.CrossRef
10.
go back to reference Brück, W. 2005. Inflammatory demyelination is not central to the pathogenesis of multiple sclerosis. Journal of neurology. 252 (5): v10–v15.CrossRef Brück, W. 2005. Inflammatory demyelination is not central to the pathogenesis of multiple sclerosis. Journal of neurology. 252 (5): v10–v15.CrossRef
11.
go back to reference Lassmann, H., J. Van Horssen, and D. Mahad. 2012. Progressive multiple sclerosis: Pathology and pathogenesis. Nature Reviews Neurology. 8 (11): 647–656.CrossRef Lassmann, H., J. Van Horssen, and D. Mahad. 2012. Progressive multiple sclerosis: Pathology and pathogenesis. Nature Reviews Neurology. 8 (11): 647–656.CrossRef
12.
go back to reference Astier, A.L., and D.A. Hafler. 2007. Abnormal Tr1 differentiation in multiple sclerosis. Journal of neuroimmunology. 191 (1–2): 70–78.CrossRef Astier, A.L., and D.A. Hafler. 2007. Abnormal Tr1 differentiation in multiple sclerosis. Journal of neuroimmunology. 191 (1–2): 70–78.CrossRef
13.
go back to reference Ireland, S.J., N.L. Monson, and L.S. Davis. 2015. Seeking balance: Potentiation and inhibition of multiple sclerosis autoimmune responses by IL-6 and IL-10. Cytokine 73 (2): 236–244.CrossRef Ireland, S.J., N.L. Monson, and L.S. Davis. 2015. Seeking balance: Potentiation and inhibition of multiple sclerosis autoimmune responses by IL-6 and IL-10. Cytokine 73 (2): 236–244.CrossRef
14.
go back to reference Mari, E.R., J.N. Moore, G.X. Zhang, and A. Rostami. 2015. Mechanisms of immunological tolerance in central nervous system inflammatory demyelination. Clinical and Experimental Neuroimmunology. 6 (3): 264–274.CrossRef Mari, E.R., J.N. Moore, G.X. Zhang, and A. Rostami. 2015. Mechanisms of immunological tolerance in central nervous system inflammatory demyelination. Clinical and Experimental Neuroimmunology. 6 (3): 264–274.CrossRef
15.
go back to reference Hur, E.M., S. Youssef, M.E. Haws, S.Y. Zhang, R.A. Sobel, and L. Steinman. 2007. Osteopontin-induced relapse and progression of autoimmune brain disease through enhanced survival of activated T cells. Nature immunology. 8 (1): 74–83.CrossRef Hur, E.M., S. Youssef, M.E. Haws, S.Y. Zhang, R.A. Sobel, and L. Steinman. 2007. Osteopontin-induced relapse and progression of autoimmune brain disease through enhanced survival of activated T cells. Nature immunology. 8 (1): 74–83.CrossRef
16.
go back to reference Jansson, M., V. Panoutsakopoulou, J. Baker, L. Klein, and H. Cantor. 2002. Cutting edge: Attenuated experimental autoimmune encephalomyelitis in eta-1/osteopontin-deficient mice. The Journal of Immunology. 168 (5): 2096–2099.CrossRef Jansson, M., V. Panoutsakopoulou, J. Baker, L. Klein, and H. Cantor. 2002. Cutting edge: Attenuated experimental autoimmune encephalomyelitis in eta-1/osteopontin-deficient mice. The Journal of Immunology. 168 (5): 2096–2099.CrossRef
17.
go back to reference Kasinski, A.L., and F.J. Slack. 2011. MicroRNAs en route to the clinic: Progress in validating and targeting microRNAs for cancer therapy. Nature Reviews Cancer. 11 (12): 849–864.CrossRef Kasinski, A.L., and F.J. Slack. 2011. MicroRNAs en route to the clinic: Progress in validating and targeting microRNAs for cancer therapy. Nature Reviews Cancer. 11 (12): 849–864.CrossRef
18.
go back to reference Tufekci, K.U., M.G. Oner, S. Genc, and K. Genc. 2011. MicroRNAs and multiple sclerosis. Autoimmune diseases. 2011. Tufekci, K.U., M.G. Oner, S. Genc, and K. Genc. 2011. MicroRNAs and multiple sclerosis. Autoimmune diseases. 2011.
19.
go back to reference Gandhi, R., B. Healy, T. Gholipour, S. Egorova, A. Musallam, M.S. Hussain, et al. 2013. Circulating microRNAs as biomarkers for disease staging in multiple sclerosis. Annals of neurology. 73 (6): 729–740.CrossRef Gandhi, R., B. Healy, T. Gholipour, S. Egorova, A. Musallam, M.S. Hussain, et al. 2013. Circulating microRNAs as biomarkers for disease staging in multiple sclerosis. Annals of neurology. 73 (6): 729–740.CrossRef
20.
go back to reference Sharma, A., M. Kumar, J. Aich, M. Hariharan, S.K. Brahmachari, A. Agrawal, et al. 2009. Posttranscriptional regulation of interleukin-10 expression by hsa-miR-106a. Proceedings of the National Academy of Sciences. 106 (14): 5761–5766.CrossRef Sharma, A., M. Kumar, J. Aich, M. Hariharan, S.K. Brahmachari, A. Agrawal, et al. 2009. Posttranscriptional regulation of interleukin-10 expression by hsa-miR-106a. Proceedings of the National Academy of Sciences. 106 (14): 5761–5766.CrossRef
21.
go back to reference Jiang, L., Z. Cheng, S. Qiu, Z. Que, W. Bao, C. Jiang, et al. 2012. Altered let-7 expression in Myasthenia gravis and let-7c mediated regulation of IL-10 by directly targeting IL-10 in Jurkat cells. International immunopharmacology. 14 (2): 217–223.CrossRef Jiang, L., Z. Cheng, S. Qiu, Z. Que, W. Bao, C. Jiang, et al. 2012. Altered let-7 expression in Myasthenia gravis and let-7c mediated regulation of IL-10 by directly targeting IL-10 in Jurkat cells. International immunopharmacology. 14 (2): 217–223.CrossRef
22.
go back to reference Shevde, L.A., B.J. Metge, A. Mitra, Y. Xi, J. Ju, J.A. King, et al. 2010. Spheroid-forming subpopulation of breast cancer cells demonstrates vasculogenic mimicry via hsa-miR-299–5p regulated de novo expression of osteopontin. Journal of cellular and molecular medicine. 14 (6b): 1693–1706.CrossRef Shevde, L.A., B.J. Metge, A. Mitra, Y. Xi, J. Ju, J.A. King, et al. 2010. Spheroid-forming subpopulation of breast cancer cells demonstrates vasculogenic mimicry via hsa-miR-299–5p regulated de novo expression of osteopontin. Journal of cellular and molecular medicine. 14 (6b): 1693–1706.CrossRef
23.
go back to reference Hung, P.-S., F.-C. Chen, S.-H. Kuang, S.-Y. Kao, S.-C. Lin, and K.-W. Chang. 2010. miR-146a induces differentiation of periodontal ligament cells. Journal of dental research. 89 (3): 252–257.CrossRef Hung, P.-S., F.-C. Chen, S.-H. Kuang, S.-Y. Kao, S.-C. Lin, and K.-W. Chang. 2010. miR-146a induces differentiation of periodontal ligament cells. Journal of dental research. 89 (3): 252–257.CrossRef
24.
go back to reference Hurst, D.R., M.D. Edmonds, G.K. Scott, C.C. Benz, K.S. Vaidya, and D.R. Welch. 2009. Breast cancer metastasis suppressor 1 up-regulates miR-146, which suppresses breast cancer metastasis. Cancer research. 69 (4): 1279–1283.CrossRef Hurst, D.R., M.D. Edmonds, G.K. Scott, C.C. Benz, K.S. Vaidya, and D.R. Welch. 2009. Breast cancer metastasis suppressor 1 up-regulates miR-146, which suppresses breast cancer metastasis. Cancer research. 69 (4): 1279–1283.CrossRef
25.
go back to reference Tang, H., Y. Lai, J. Zheng, K. Chen, H. Jiang, and G. Xu. 2020. miR-146a promotes tolerogenic properties of dendritic cells and through targeting Notch1 signaling. Immunological investigations. 49 (5): 555–570.CrossRef Tang, H., Y. Lai, J. Zheng, K. Chen, H. Jiang, and G. Xu. 2020. miR-146a promotes tolerogenic properties of dendritic cells and through targeting Notch1 signaling. Immunological investigations. 49 (5): 555–570.CrossRef
26.
go back to reference Csepany, T. 2018. Diagnosis of multiple sclerosis: A review of the 2017 revisions of the McDonald criteria. Ideggyogyaszati szemle. 71 (9–10): 321–329.CrossRef Csepany, T. 2018. Diagnosis of multiple sclerosis: A review of the 2017 revisions of the McDonald criteria. Ideggyogyaszati szemle. 71 (9–10): 321–329.CrossRef
27.
go back to reference Calabresi, P.A. 2004. Diagnosis and management of multiple sclerosis. American family physician. 70 (10): 1935–1944.PubMed Calabresi, P.A. 2004. Diagnosis and management of multiple sclerosis. American family physician. 70 (10): 1935–1944.PubMed
28.
go back to reference Hauser, S.L. 1994. Multiple sclerosis and other demyelinating diseases. Harrison’s principles of internal medicine. 1994;2287. Hauser, S.L. 1994. Multiple sclerosis and other demyelinating diseases. Harrison’s principles of internal medicine. 1994;2287.
29.
go back to reference Montalban, X., M. Tintore, J. Swanton, F. Barkhof, F. Fazekas, M. Filippi, et al. 2010. MRI criteria for MS in patients with clinically isolated syndromes. Neurology 74 (5): 427–434.CrossRef Montalban, X., M. Tintore, J. Swanton, F. Barkhof, F. Fazekas, M. Filippi, et al. 2010. MRI criteria for MS in patients with clinically isolated syndromes. Neurology 74 (5): 427–434.CrossRef
30.
go back to reference Comabella, M., I. Pericot, R. Goertsches, C. Nos, M. Castillo, J.B. Navarro, et al. 2005. Plasma osteopontin levels in multiple sclerosis. Journal of neuroimmunology. 158 (1–2): 231–239.CrossRef Comabella, M., I. Pericot, R. Goertsches, C. Nos, M. Castillo, J.B. Navarro, et al. 2005. Plasma osteopontin levels in multiple sclerosis. Journal of neuroimmunology. 158 (1–2): 231–239.CrossRef
31.
go back to reference Zaffran, Y., O. Destaing, A. Roux, S. Ory, T. Nheu, P. Jurdic, et al. 2001. CD46/CD3 costimulation induces morphological changes of human T cells and activation of Vav, Rac, and extracellular signal-regulated kinase mitogen-activated protein kinase. The Journal of Immunology. 167 (12): 6780–6785.CrossRef Zaffran, Y., O. Destaing, A. Roux, S. Ory, T. Nheu, P. Jurdic, et al. 2001. CD46/CD3 costimulation induces morphological changes of human T cells and activation of Vav, Rac, and extracellular signal-regulated kinase mitogen-activated protein kinase. The Journal of Immunology. 167 (12): 6780–6785.CrossRef
32.
go back to reference Dai, H., B. Ciric, G.-X. Zhang, and A. Rostami. 2012. Interleukin-10 plays a crucial role in suppression of experimental autoimmune encephalomyelitis by Bowman-Birk inhibitor. Journal of neuroimmunology. 245 (1–2): 1–7.CrossRef Dai, H., B. Ciric, G.-X. Zhang, and A. Rostami. 2012. Interleukin-10 plays a crucial role in suppression of experimental autoimmune encephalomyelitis by Bowman-Birk inhibitor. Journal of neuroimmunology. 245 (1–2): 1–7.CrossRef
33.
go back to reference Ma, A., Z. Xiong, Y. Hu, S. Qi, L. Song, H. Dun, et al. 2009. Dysfunction of IL-10-producing type 1 regulatory T cells and CD4+ CD25+ regulatory T cells in a mimic model of human multiple sclerosis in Cynomolgus monkeys. International immunopharmacology. 9 (5): 599–608.CrossRef Ma, A., Z. Xiong, Y. Hu, S. Qi, L. Song, H. Dun, et al. 2009. Dysfunction of IL-10-producing type 1 regulatory T cells and CD4+ CD25+ regulatory T cells in a mimic model of human multiple sclerosis in Cynomolgus monkeys. International immunopharmacology. 9 (5): 599–608.CrossRef
34.
go back to reference Martinez‐Forero, I., R. Garcia‐Munoz, S. Martinez‐Pasamar, S. Inoges, A. Lopez‐Diaz de Cerio, and R. Palacios, et al. 2008. IL‐10 suppressor activity and ex vivo Tr1 cell function are impaired in multiple sclerosis. European Journal of Immunology. 38(2):576–86. Martinez‐Forero, I., R. Garcia‐Munoz, S. Martinez‐Pasamar, S. Inoges, A. Lopez‐Diaz de Cerio, and R. Palacios, et al. 2008. IL‐10 suppressor activity and ex vivo Tr1 cell function are impaired in multiple sclerosis. European Journal of Immunology. 38(2):576–86.
35.
go back to reference Braitch, M., and S.C. Constantinescu. 2010. The role of osteopontin in experimental autoimmune encephalomyelitis (EAE) and multiple sclerosis (MS). Inflammation & Allergy-Drug Targets (Formerly Current Drug Targets-Inflammation & Allergy)(Discontinued). 9(4):249–56. Braitch, M., and S.C. Constantinescu. 2010. The role of osteopontin in experimental autoimmune encephalomyelitis (EAE) and multiple sclerosis (MS). Inflammation & Allergy-Drug Targets (Formerly Current Drug Targets-Inflammation & Allergy)(Discontinued). 9(4):249–56.
36.
go back to reference Matejčíková, Z., J. Mareš, H.P. Vranová, J. Klosova, V. Sladkova, J. Dolakova, et al. 2015. Cerebrospinal fluid inflammatory markers in patients with multiple sclerosis: A pilot study. Journal of Neural Transmission. 122 (2): 273–277.CrossRef Matejčíková, Z., J. Mareš, H.P. Vranová, J. Klosova, V. Sladkova, J. Dolakova, et al. 2015. Cerebrospinal fluid inflammatory markers in patients with multiple sclerosis: A pilot study. Journal of Neural Transmission. 122 (2): 273–277.CrossRef
37.
go back to reference Dimisianos, N., M. Rodi, D. Kalavrizioti, V. Georgiou, P. Papathanasopoulos, A. Mouzaki. 2014. Cytokines as biomarkers of treatment response to IFNβ in relapsing-remitting multiple sclerosis. Multiple Sclerosis International. 2014;2014. Dimisianos, N., M. Rodi, D. Kalavrizioti, V. Georgiou, P. Papathanasopoulos, A. Mouzaki. 2014. Cytokines as biomarkers of treatment response to IFNβ in relapsing-remitting multiple sclerosis. Multiple Sclerosis International. 2014;2014.
38.
go back to reference Trenova, A.G., G.S. Slavov, M.G. Manova, and I.I. Kostadinova. 2014. Cytokines and disability in interferon-β-1b treated and untreated women with multiple sclerosis. Archives of medical research. 45 (6): 495–500.CrossRef Trenova, A.G., G.S. Slavov, M.G. Manova, and I.I. Kostadinova. 2014. Cytokines and disability in interferon-β-1b treated and untreated women with multiple sclerosis. Archives of medical research. 45 (6): 495–500.CrossRef
39.
go back to reference Lu, L.-F., M.P. Boldin, A. Chaudhry, L.-L. Lin, K.D. Taganov, T. Hanada, et al. 2010. Function of miR-146a in controlling Treg cell-mediated regulation of Th1 responses. Cell 142 (6): 914–929.CrossRef Lu, L.-F., M.P. Boldin, A. Chaudhry, L.-L. Lin, K.D. Taganov, T. Hanada, et al. 2010. Function of miR-146a in controlling Treg cell-mediated regulation of Th1 responses. Cell 142 (6): 914–929.CrossRef
40.
go back to reference Tang, Y., X. Luo, H. Cui, X. Ni, M. Yuan, Y. Guo, et al. 2009. MicroRNA-146a contributes to abnormal activation of the type I interferon pathway in human lupus by targeting the key signaling proteins. Arthritis & Rheumatism: Official Journal of the American College of Rheumatology. 60 (4): 1065–1075.CrossRef Tang, Y., X. Luo, H. Cui, X. Ni, M. Yuan, Y. Guo, et al. 2009. MicroRNA-146a contributes to abnormal activation of the type I interferon pathway in human lupus by targeting the key signaling proteins. Arthritis & Rheumatism: Official Journal of the American College of Rheumatology. 60 (4): 1065–1075.CrossRef
41.
go back to reference Alexandrov, P.N., P. Dua, and W.J. Lukiw. 2014. Up-regulation of miRNA-146a in progressive, age-related inflammatory neurodegenerative disorders of the human CNS. Frontiers in neurology. 5: 181.CrossRef Alexandrov, P.N., P. Dua, and W.J. Lukiw. 2014. Up-regulation of miRNA-146a in progressive, age-related inflammatory neurodegenerative disorders of the human CNS. Frontiers in neurology. 5: 181.CrossRef
42.
go back to reference Yu, J.-H., L. Long, Z.-X. Luo, L.-M. Li, and J.-R. You. 2016. Anti-inflammatory role of microRNA let-7c in LPS treated alveolar macrophages by targeting STAT3. Asian Pacific journal of tropical medicine. 9 (1): 72–75.CrossRef Yu, J.-H., L. Long, Z.-X. Luo, L.-M. Li, and J.-R. You. 2016. Anti-inflammatory role of microRNA let-7c in LPS treated alveolar macrophages by targeting STAT3. Asian Pacific journal of tropical medicine. 9 (1): 72–75.CrossRef
43.
go back to reference Satoh, J.I., Y. Kino, and S. Niida. 2015. MicroRNA-Seq data analysis pipeline to identify blood biomarkers for Alzheimer’s disease from public data. Biomarker Insights. 10:BMI. S25132. Satoh, J.I., Y. Kino, and S. Niida. 2015. MicroRNA-Seq data analysis pipeline to identify blood biomarkers for Alzheimer’s disease from public data. Biomarker Insights. 10:BMI. S25132.
44.
go back to reference Zhang, Y., C. Liu, J. Wang, Q. Li, H. Ping, S. Gao, et al. 2016. MiR-299-5p regulates apoptosis through autophagy in neurons and ameliorates cognitive capacity in APPswe/PS1dE9 mice. Scientific reports. 6 (1): 1–14.CrossRef Zhang, Y., C. Liu, J. Wang, Q. Li, H. Ping, S. Gao, et al. 2016. MiR-299-5p regulates apoptosis through autophagy in neurons and ameliorates cognitive capacity in APPswe/PS1dE9 mice. Scientific reports. 6 (1): 1–14.CrossRef
45.
go back to reference Azarbarzin, S., M.A.H. Feizi, R. Safaralizadeh, R. Ravanbakhsh, M. Kazemzadeh, A. Fateh, et al. 2016. The value of miR-299-5p in diagnosis and prognosis of intestinal-type gastric adenocarcinoma. Biochemical genetics. 54 (4): 413–420.CrossRef Azarbarzin, S., M.A.H. Feizi, R. Safaralizadeh, R. Ravanbakhsh, M. Kazemzadeh, A. Fateh, et al. 2016. The value of miR-299-5p in diagnosis and prognosis of intestinal-type gastric adenocarcinoma. Biochemical genetics. 54 (4): 413–420.CrossRef
46.
go back to reference Majd, M., A. Hosseini, K. Ghaedi, A. Kiani-Esfahani, S. Tanhaei, H. Shiralian-Esfahani, et al. 2018. MiR-9-5p and miR-106a-5p dysregulated in CD4+ T-cells of multiple sclerosis patients and targeted essential factors of T helper17/regulatory T-cells differentiation. Iranian journal of basic medical sciences. 21 (3): 277.PubMedPubMedCentral Majd, M., A. Hosseini, K. Ghaedi, A. Kiani-Esfahani, S. Tanhaei, H. Shiralian-Esfahani, et al. 2018. MiR-9-5p and miR-106a-5p dysregulated in CD4+ T-cells of multiple sclerosis patients and targeted essential factors of T helper17/regulatory T-cells differentiation. Iranian journal of basic medical sciences. 21 (3): 277.PubMedPubMedCentral
47.
go back to reference Rahimirad, S., M. Navaderi, S. Alaei, and M.H. Sanati. 2021. Identification of hsa-miR-106a-5p as an impact agent on promotion of multiple sclerosis using multi-step data analysis. Neurological Sciences. 2021:1–9. Rahimirad, S., M. Navaderi, S. Alaei, and M.H. Sanati. 2021. Identification of hsa-miR-106a-5p as an impact agent on promotion of multiple sclerosis using multi-step data analysis. Neurological Sciences. 2021:1–9.
Metadata
Title
Identification of Potential Biomarkers in the Peripheral Blood Mononuclear Cells of Relapsing–Remitting Multiple Sclerosis Patients
Authors
Marjan Golabi
Farshid Fathi
Morteza Samadi
Mohammad Sadegh Hesamian
Nahid Eskandari
Publication date
28-03-2022
Publisher
Springer US
Published in
Inflammation / Issue 4/2022
Print ISSN: 0360-3997
Electronic ISSN: 1573-2576
DOI
https://doi.org/10.1007/s10753-022-01662-9

Other articles of this Issue 4/2022

Inflammation 4/2022 Go to the issue
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discuss last year's major advances in heart failure and cardiomyopathies.